References

References

(1)      Hoehn, M. M. Parkinsonism: Onset, Progression, and Mortality. 1967, 17. https://n.neurology.org/content/neurology/17/5/427.full.pdf

(2)       Parkinson, J. An Essay on the Shaking Palsy. JNP1817, 14(2), 223–236. https://doi.org/10.1176/jnp.14.2.223.

(3)       Brissaud, É. Leçons sur les maladies nerveuses; Masson, 1899.

(4)       LEWY, F. Paralysis Agitans. I. Pathologische Anatomie. Handbuch der Neurologie1912.

(5)       Polymeropoulos, M. H.; Lavedan, C.; Leroy, E.; Ide, S. E.; Dehejia, A.; Dutra, A.; Pike, B.; Root, H.; Rubenstein, J.; Boyer, R.; Stenroos, E. S.; Chandrasekharappa, S.; Athanassiadou, A.; Papapetropoulos, T.; Johnson, W. G.; Lazzarini, A. M.; Duvoisin, R. C.; Iorio, G. D.; Golbe, L. I.; Nussbaum, R. L. Mutation in the α-Synuclein Gene Identified in Families with Parkinson’s Disease. Science1997, 276(5321), 2045–2047. https://doi.org/10.1126/science.276.5321.2045.

(6)       Spillantini, M. G.; Schmidt, M. L.; Lee, V. M.-Y.; Trojanowski, J. Q.; Jakes, R.; Goedert, M. α-Synuclein in Lewy Bodies. Nature1997, 388(6645), 839–840. https://doi.org/10.1038/42166.

(7)       Siddiqui, I. J.; Pervaiz, N.; Abbasi, A. A. The Parkinson Disease Gene SNCA: Evolutionary and Structural Insights with Pathological Implication. Sci Rep2016,6. https://doi.org/10.1038/srep24475.

(8)       Alkanli, N.; Ay, A. The Relationship between Alpha-Synuclein (SNCA) Gene Polymorphisms and Development Risk of Parkinson’s Disease. Synucleins – Biochemistry and Role in Diseases2019. https://doi.org/10.5772/intechopen.82808.

(9)       Pardo, L. M.; van Duijn, C. M. In Search of Genes Involved in Neurodegenerative Disorders. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis2005, 592(1), 89–101. https://doi.org/10.1016/j.mrfmmm.2005.06.006.

(10)     Hardy, J.; Lewis, P.; Revesz, T.; Lees, A.; Paisan-Ruiz, C. The Genetics of Parkinson’s Syndromes: A Critical Review. Current Opinion in Genetics & Development2009, 19(3), 254–265. https://doi.org/10.1016/j.gde.2009.03.008.

(11)     Stefanis, L. α-Synuclein in Parkinson’s Disease. Cold Spring Harb Perspect Med2012, 2(2). https://doi.org/10.1101/cshperspect.a009399.

(12)     Chinta, S. J.; Andersen, J. K. Dopaminergic Neurons. Int. J. Biochem. Cell Biol.2005, 37(5), 942–946. https://doi.org/10.1016/j.biocel.2004.09.009.

(13)     Reichmann, H. Premotor Diagnosis of Parkinson’s Disease. Neurosci Bull2017, 33(5), 526–534. https://doi.org/10.1007/s12264-017-0159-5.

(14)     Seifert, K. D.; Wiener, J. I. The Impact of DaTscan on the Diagnosis and Management of Movement Disorders: A Retrospective Study. Am J Neurodegener Dis2013, 2(1), 29–34.

(15)     Van Den Eeden, S. K.; Tanner, C. M.; Bernstein, A. L.; Fross, R. D.; Leimpeter, A.; Bloch, D. A.; Nelson, L. M. Incidence of Parkinson’s Disease: Variation by Age, Gender, and Race/Ethnicity. Am J Epidemiol2003,157(11), 1015–1022. https://doi.org/10.1093/aje/kwg068.

(16)     Hawkes, C. H. The Prodromal Phase of Sporadic Parkinson’s Disease: Does It Exist and If so How Long Is It? Mov. Disord.2008,23(13), 1799–1807. https://doi.org/10.1002/mds.22242.

(17)     Ferguson, L. W.; Rajput, A. H.; Rajput, A. Early-Onset vs. Late-Onset Parkinson’s Disease: A Clinical-Pathological Study. Canadian Journal of Neurological Sciences2016, 43(1), 113–119. https://doi.org/10.1017/cjn.2015.244.

(18)     Braak, H.; Tredici, K. D.; Rüb, U.; de Vos, R. A. I.; Jansen Steur, E. N. H.; Braak, E. Staging of Brain Pathology Related to Sporadic Parkinson’s Disease. Neurobiology of Aging2003, 24(2), 197–211. https://doi.org/10.1016/S0197-4580(02)00065-9.

(19)     Sonne, J.; Reddy, V.; Beato, M. R. Neuroanatomy, Substantia Nigra. In StatPearls; StatPearls Publishing: Treasure Island (FL), 2020.

(20)     Hirsch, E.; Graybiel, A. M.; Agid, Y. A. Melanized Dopaminergic Neurons Are Differentially Susceptible to Degeneration in Parkinson’s Disease. Nature1988, 334(6180), 345–348. https://doi.org/10.1038/334345a0.

(21)     Schulz-Schaeffer, W. J. The Synaptic Pathology of α-Synuclein Aggregation in Dementia with Lewy Bodies, Parkinson’s Disease and Parkinson’s Disease Dementia. Acta Neuropathol2010, 120(2), 131–143. https://doi.org/10.1007/s00401-010-0711-0.

(22)     Meade, R. M.; Fairlie, D. P.; Mason, J. M. Alpha-Synuclein Structure and Parkinson’s Disease – Lessons and Emerging Principles. Molecular Neurodegeneration2019, 14(1), 29. https://doi.org/10.1186/s13024-019-0329-1.

(23)     Kim, W. S.; Kågedal, K.; Halliday, G. M. Alpha-Synuclein Biology in Lewy Body Diseases. Alzheimer’s Research & Therapy2014, 6(5), 73. https://doi.org/10.1186/s13195-014-0073-2.

(24)     Burré, J.; Sharma, M.; Tsetsenis, T.; Buchman, V.; Etherton, M.; Südhof, T. C. α-Synuclein Promotes SNARE-Complex Assembly in Vivo and in Vitro.Science2010, 329(5999), 1663–1667. https://doi.org/10.1126/science.1195227.

(25)     Westphal, C. H.; Chandra, S. S. Monomeric Synucleins Generate Membrane Curvature. J Biol Chem2013, 288(3), 1829–1840. https://doi.org/10.1074/jbc.M112.418871.

(26)     Power, J. H. T.; Barnes, O. L.; Chegini, F. Lewy Bodies and the Mechanisms of Neuronal Cell Death in Parkinson’s Disease and Dementia with Lewy Bodies. Brain Pathol.2017, 27(1), 3–12. https://doi.org/10.1111/bpa.12344.

(27)     Zhang, J.; Li, X.; Li, J.-D. The Roles of Post-Translational Modifications on α-Synuclein in the Pathogenesis of Parkinson’s Diseases. Front Neurosci2019, 13. https://doi.org/10.3389/fnins.2019.00381.

(28)     Sato, H.; Arawaka, S.; Hara, S.; Fukushima, S.; Koga, K.; Koyama, S.; Kato, T. Authentically Phosphorylated α-Synuclein at Ser129 Accelerates Neurodegeneration in a Rat Model of Familial Parkinson’s Disease. J Neurosci2011, 31(46), 16884–16894. https://doi.org/10.1523/JNEUROSCI.3967-11.2011.

(29)     Plotegher, N.; Gratton, E.; Bubacco, L. Number and Brightness Analysis of Alpha-Synuclein Oligomerization and the Associated Mitochondrial Morphology Alterations in Live Cells. Biochimica et Biophysica Acta (BBA) – General Subjects2014, 1840(6), 2014–2024. https://doi.org/10.1016/j.bbagen.2014.02.013.

(30)     Reeve, A. K.; Ludtmann, M. H.; Angelova, P. R.; Simcox, E. M.; Horrocks, M. H.; Klenerman, D.; Gandhi, S.; Turnbull, D. M.; Abramov, A. Y. Aggregated α-Synuclein and Complex I Deficiency: Exploration of Their Relationship in Differentiated Neurons. Cell Death Dis2015, 6(7), e1820. https://doi.org/10.1038/cddis.2015.166.

(31)     Aulić, S.; Le, T. T. N.; Moda, F.; Abounit, S.; Corvaglia, S.; Casalis, L.; Gustincich, S.; Zurzolo, C.; Tagliavini, F.; Legname, G. Defined α-Synuclein Prion-like Molecular Assemblies Spreading in Cell Culture. BMC Neurosci2014, 15, 69. https://doi.org/10.1186/1471-2202-15-69.

(32)     Ma, J.; Gao, J.; Wang, J.; Xie, A. Prion-Like Mechanisms in Parkinson’s Disease. Front Neurosci2019, 13. https://doi.org/10.3389/fnins.2019.00552.

(33)     Mahul-Mellier, A.-L.; Burtscher, J.; Maharjan, N.; Weerens, L.; Croisier, M.; Kuttler, F.; Leleu, M.; Knott, G. W.; Lashuel, H. A. The Process of Lewy Body Formation, Rather than Simply α-Synuclein Fibrillization, Is One of the Major Drivers of Neurodegeneration. Proc. Natl. Acad. Sci. U.S.A.2020, 117(9), 4971–4982. https://doi.org/10.1073/pnas.1913904117.

(34)     Paumier, K. L.; Sukoff Rizzo, S. J.; Berger, Z.; Chen, Y.; Gonzales, C.; Kaftan, E.; Li, L.; Lotarski, S.; Monaghan, M.; Shen, W.; Stolyar, P.; Vasilyev, D.; Zaleska, M.; D. Hirst, W.; Dunlop, J. Behavioral Characterization of A53T Mice Reveals Early and Late Stage Deficits Related to Parkinson’s Disease. PLoS One2013, 8(8). https://doi.org/10.1371/journal.pone.0070274.

(35)     Heman-Ackah, S. M.; Manzano, R.; Hoozemans, J. J.; Scheper, W.; Flynn, R.; Haerty, W.; Cowley, S. A.; Bassett, A. R.; Wood, M. J. Alpha-Synuclein Induces the Unfolded Protein Response in Parkinson’s Disease SNCA Triplication IPSC-Derived Neurons. Hum Mol Genet2017, 26(22), 4441–4450. https://doi.org/10.1093/hmg/ddx331.

(36)     Dawson, T. M.; Dawson, V. L. The Role of Parkin in Familial and Sporadic Parkinson’s Disease. Mov Disord2010, 25(0 1), S32–S39. https://doi.org/10.1002/mds.22798.

(37)     Sriram, S. R.; Li, X.; Ko, H. S.; Chung, K. K. K.; Wong, E.; Lim, K. L.; Dawson, V. L.; Dawson, T. M. Familial-Associated Mutations Differentially Disrupt the Solubility, Localization, Binding and Ubiquitination Properties of Parkin. Hum Mol Genet2005, 14(17), 2571–2586. https://doi.org/10.1093/hmg/ddi292.

(38)     Ordenstein, L.; Royal College of Surgeons of England. Sur la paralysie agitante et la sclérose en plaques généralisée; Paris : A. Delahaye, 1868.

(39)     Hallett, M.; Litvan, I. Evaluation of Surgery for Parkinson’s Disease: A Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology1999, 53(9), 1910–1910. https://doi.org/10.1212/WNL.53.9.1910.

(40)     Ponce, F. A.; Lozano, A. M. The Surgical Management of Parkinson’s Disease. CNS Neurol Disord Drug Targets2011, 10(6), 685–692. https://doi.org/10.2174/187152711797247795.

(41)     Duker, A. P.; Espay, A. J. Surgical Treatment of Parkinson’s Disease: Past, Present, and Future. Neurol Clin2013, 31(3), 799–808. https://doi.org/10.1016/j.ncl.2013.03.007.

(42)     Cotzias, G. C.; Papavasiliou, P. S.; Gellene, R. Modification of Parkinsonism — Chronic Treatment with L-Dopa. New England Journal of Medicine1969, 280(7), 337–345. https://doi.org/10.1056/NEJM196902132800701.

(43)     Konta, B.; Frank, W. The Treatment of Parkinson’s Disease with Dopamine Agonists. GMS Health Technol Assess2008, 4.

(44)     Groiss, S. J.; Wojtecki, L.; Südmeyer, M.; Schnitzler, A. Deep Brain Stimulation in Parkinson’s                Disease. Ther Adv Neurol Disord2009, 2(6), 20–28. https://doi.org/10.1177/1756285609339382.

(45)     Charcot, J. M. Lecons sur, les maladies du système nerveux; Lecrosnier et Babé, 1886.